Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by tamarindo1on Dec 26, 2020 9:57am
218 Views
Post# 32183571

Antibody treatment

Antibody treatment

A new antibody treatment with the potential to give people instant immunity after being exposed to Covid-19 and prevent illness is being trialled by British scientists in the UK. 

The drug would offer immediate and long-term protection to patients when it would be too late to offer a vaccine, potentially saving thousands of lives.

It could be given as an emergency treatment to hospital inpatients, care home residents and university students to help reduce the spread of the virus.  

People who live with someone has caught Covid or been exposed to them could be injected with the drug to stop them becoming infected, even if they have not had a coronavirus vaccine.

British scientists from the University College London Hospitals NHS (UCLH) have already injected ten people with the drug as part of the new trial called Storm Chaser, with an aim to trial the new treatment on 1,125 people globally. The participants received two consecutive doses of the drug.

They hope the treatment would provide protection from Covid-19 for between six months to a year. 

Scientists from the UCLH have also begun a second clinical trial named Provent, to examine the use of the antibody for people who may not benefit from vaccines, such as patients with a compromised immune system, or those at increased risk of Covid-19 infection due to factors such as age and existing conditions. 

UCLH injected the ten people - including medical staff and university students - as part of the Storm Chaser trial at its new vaccine research centre after the study entered phase three trials on December 2.  

Key groups of the trial include healthcare workers, students who live in shared accommodation and patients who have been recently exposed to anyone with Covid-19, as well as those in long-term care, the military and industry staff such as factory workers.

In the first trial, the antibody, known as AZD7442, has been developed by pharmaceutical company AstraZeneca, which has also created a vaccine with Oxford University that is awaiting approval for use by the Medicines and Healthcare products Regulatory Agency (MHRA).

Meanwhile, older people and those in long-term care, as well as people with conditions such as cancer and HIV, will be recruited to take part in the Provent trial. 

NHS England national medical director Professor Stephen Powis said: 'The continuing contribution of the NHS to pioneering global efforts to fight Covid-19 is remarkable.

'These two clinical trials are an important addition to testing new therapeutic approaches, as antibody treatments may offer an alternative to patient groups who cannot benefit from a vaccine, such as immunocompromised patients.' 

UCLH virologist Dr Catherine Houlihan, who is leading the Storm Chaser trial, said: 'We know that this antibody combination can neutralise the virus, so we hope to find that giving this treatment via injection can lead to immediate protection against the development of Covid-19 in people who have been exposed - when it would be too late to offer a vaccine.'

Dr Houlihan said the treatment would be an 'exciting addition' to the efforts being tested and developed to fight corovavirus, reports The Guardian.   

'If we can prove that this treatment works and prevent people who are exposed to the virus going on to develop Covid-19, it would be an exciting addition to the arsenal of weapons being developed to fight this dreadful virus,' she said.  

UCLH infectious diseases consultant Dr Nicky Longley, who is leading the university's portion of Provent, said: 'We want to reassure anyone for whom a vaccine may not work that we can offer an alternative which is just as protective.'  

Paul Hunter, a professor of medicine at the University of East Anglia and an expert in infectious diseases, said the new treatment in the Storm Chaser trial could save thousands of lives. 

'If you are dealing with outbreaks in settings such as care homes, or if you have got patients who are particularly at risk of getting severe Covid, such as the elderly, then this could well save a lot of lives. Providing it's borne out in phase 3 trials, it could play a big role in keeping alive people who would otherwise die. So it should be a big thing,' he said.

'If you had an outbreak in a care home, you might want to use these sorts of cocktails of antibodies to bring the outbreak under control as soon as possible by giving the drug to everybody in the care home – residents and staff – who hasn't been vaccinated. 

'Similarly, if you live with your elderly grandmother and you or someone else in the house gets infected, then you could give her this to protect her.' 

The potential breakthrough in the instant immunity treatment is welcome news to millions of Brits who are facing Tier 4 restrictions amid rising coronavirus cases.

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse